Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + metronomic temozolomide for recurrent high-grade glioma
NL-OMON30453Phase 2Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and temozolomide in glioma and glioblastoma (GBM), sponsored by Amsterdam University Medical Center. Primary endpoint: Progression-free survival at 6 months. Planned start Feb 2007; status: not yet recruiting.
02
Drugs
bevacizumabtemozolomide
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON30453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30453.